<DOC>
	<DOC>NCT00542880</DOC>
	<brief_summary>This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.</brief_summary>
	<brief_title>Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatient, female or male aged ≥40 years, diagnosis of COPD with symptoms for at least 2 years FEV1 ≤50% of predicted normal value, prebronchodilator, FEV1/VC &lt;70% Prebronchodilator Current respiratory tract disorder other than COPD History of asthma or rhinitis Significant or unstable cardiovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Symbicort</keyword>
	<keyword>Seretide</keyword>
</DOC>